COVID-19 immunews: antibody protection may last long in severe survivors

Most people who are exposed to SARS-CoV-2, the coronavirus that causes COVID-19, only experience mild symptoms or none at all. However, the infection can still pass from them to other people, and the overall case fatality rate appears to be converging on 0.5–1.0%. It is, therefore, important to establish whether individuals who have contracted the virus once can contract it again and become contagious, or whether they are immune to future infection. According to Dr. Marcus Buggert, an immunologist at the Karolinska Institutet in Solna, Sweden, n the absence of a protective vaccine, it is critical to determine if exposed or infected people, especially those with asymptomatic or very mild forms of the disease who likely act inadvertently as the major transmitters, develop robust adaptive immune responses against SARS-CoV-2. Research suggests that not all individuals who have contracted SARS-CoV-2 in the past produce antibodies capable of neutralizing the virus, particularly if they only experienced a mild infection.

Studies have also found that immune cells known as memory B cells, which produce antibodies against previously encountered infections, tend to be short-lived after infection with the closely related coronavirus SARS-CoV, which causes severe acute respiratory syndrome (SARS). In contrast, another type of immune cell called a memory T cell, which can recognize a previously encountered pathogen and initiate an immune response to it, may persist for years after the initial infection. In a new study, memory T cells protected against SARS-CoV-2 infection, even in the absence of antibodies against the virus.  In the new research, Buggert and his colleagues investigated the immune status of 206 individuals in Sweden, where measures to control the spread of SARS-CoV-2 have been less strict than in other European countries.

Their participants fell into five categories:

  • people with ongoing moderate or severe COVID-19
  • individuals convalescing after a mild or severe infection
  • asymptomatic family members exposed to the infection
  • healthy individuals who donated blood during the pandemic
  • healthy individuals who donated blood in 2019, before the pandemic

As expected, the team found strong memory T-cell responses and high levels of antibodies specific to the virus in all 23 people who had recovered from severe COVID-19. More surprisingly, 30 of the 31 people who recovered from a mild infection had memory T-cell responses to the virus, and 27 had antibodies against it. Out of 28 family members exposed to an infected individual, 26 were able to mount T-cell responses to the virus, and 17 had antibodies against it. Even after a very mild infection, memory T-cell responses were often detectable months later, sometimes even in the absence of SARS-CoV-2 antibodies. Remarkably, in 28% of those who had donated blood samples in 2019, before the current pandemic, the researchers detected T cells that reacted to SARS-CoV-2. The researchers believe that this reflects immunity induced by exposure to other coronaviruses that have protein sequences in common with SARS-CoV-2.

Dr. Buggert stated: “Our findings suggest that the reliance on antibody responses may underestimate the extent of population-level immunity against SARS-CoV-2. The obvious next step is to determine whether robust memory T-cell responses in the absence of detectable antibodies can protect against COVID-19 in the long term. Our collective dataset shows that SARS-CoV-2 elicits robust, broad, and highly functional memory T-cell responses, suggesting that natural exposure or infection may prevent recurrent episodes of severe COVID-19. We speculate that these responses may provide some protection against the new coronavirus, though direct evidence for this is currently lacking. In addition, we show that rhesus macaques infected with SARS-CoV-2 develop almost complete immunity against future infections with the virus. We acknowledge, however, that the study was limited by the small numbers in each group and lack of clinical follow-up.

It, therefore, remains to be determined if robust memory T-cell responses in the absence of detectable circulating antibodies can protect against severe forms of COVID-19. Thus far, however, none of the individuals in their study who recovered from the infection have experienced further episodes of COVID-19. There is, however, an exception: a 33-old subject that wes hospitalized in Chicago last April for COVID-19, survived and it went in Europe after borders reopening, returning back from Spain via United Kingdom. Two days ago has been again hospitalized for COVID-10 positivity.

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Maucourant C et al. Sci Immunol 2020 Aug 21; 5(50):eabd6832.

Sekine T et al., Buggert M. Sci Immunol. 2020 Jul; 5(49):eaba7918. 

Schmidt F, Weisblum Y et al. J Exp Med. 2020; 217(11):e20201181. 

0 0 vote
Article Rating
Informazioni su Dott. Gianfrancesco Cormaci 2443 Articoli
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry specialty in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Detentore di un brevetto sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento immunologicamente neutralizzata (owner of a patent concerning the production of bakery gluten-free products, starting from regular wheat flour). - Responsabile del reparto Ricerca e Sviluppo per la società CoFood s.r.l. (leader of the R&D for the partnership CoFood s.r.l.) - Autore di un libro riguardante la salute e l'alimentazione, con approfondimenti su come questa condizioni tutti i sistemi corporei. - Autore di articoli su informazione medica, salute e benessere sui siti web salutesicilia.com e medicomunicare.it
Subscribe
Notificami

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.

0 Commenti
Inline Feedbacks
View all comments